Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Motokazu Sugimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1654-0613; OpenAlex author ID A5022285016. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 16

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  2. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  3. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  4. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  5. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  6. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  7. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  8. Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.15853↗
  9. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.3892/or.2022.8332↗
  10. Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001539↗
  11. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001547↗
  12. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Co-author DOI 10.1002/jso.25681↗
  13. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  14. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-018-3695-z↗
  15. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  16. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. Co-author DOI 10.1097/mpa.0000000000001106↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shin Kobayashi · 5 shared papers, 2018–2023 · strength 0.61
  2. Naoto Gotohda · 5 shared papers, 2018–2023 · strength 0.61
  3. Motohiro Kojima · 4 shared papers, 2018–2023 · strength 0.49
  4. Shinichiro Takahashi · 4 shared papers, 2018–2022 · strength 0.46
  5. Tomohisa Otsu · 2 shared papers, 2026 · strength 0.45
  6. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.45
  7. Masamichi Hayashi · 2 shared papers, 2026 · strength 0.45
  8. Shinji Mii · 2 shared papers, 2026 · strength 0.45
  9. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  10. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  11. Junpei Yamaguchi · 2 shared papers, 2026 · strength 0.45
  12. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  13. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  14. Nobuhiko Nakagawa · 2 shared papers, 2026 · strength 0.45
  15. Yukihiro Yokoyama · 2 shared papers, 2026 · strength 0.45
  16. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  17. Keizo Fujita · 2 shared papers, 2026 · strength 0.45
  18. Horacio Cabral · 3 shared papers, 2020–2023 · strength 0.41
  19. Masashi Kudo · 3 shared papers, 2020–2023 · strength 0.41
  20. Naoki Takahashi · 4 shared papers, 2018–2019 · strength 0.29
  21. Atsushi Enomoto · 1 shared paper, 2026 · strength 0.22
  22. Gloria M. Petersen · 3 shared papers, 2018–2019 · strength 0.20
  23. Michael B. Farnell · 2 shared papers, 2018–2019 · strength 0.17
  24. Michael L. Kendrick · 2 shared papers, 2018–2019 · strength 0.17
  25. Mark Joseph Truty · 2 shared papers, 2018–2019 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.